Marinus Pharmaceuticals (MRNS) Set to Announce Earnings on Wednesday

Marinus Pharmaceuticals (NASDAQ:MRNS) will post its quarterly earnings results before the market opens on Wednesday, May 8th. Analysts expect Marinus Pharmaceuticals to post earnings of ($0.68) per share for the quarter.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. The business had revenue of $7.19 million for the quarter, compared to analysts’ expectations of $7.78 million. During the same quarter last year, the firm earned ($0.76) earnings per share. On average, analysts expect Marinus Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Marinus Pharmaceuticals Stock Up 2.4 %

Marinus Pharmaceuticals stock traded up $0.04 during midday trading on Tuesday, reaching $1.52. The company’s stock had a trading volume of 261,949 shares, compared to its average volume of 1,446,914. Marinus Pharmaceuticals has a 52-week low of $1.11 and a 52-week high of $11.26. The company has a current ratio of 4.07, a quick ratio of 4.01 and a debt-to-equity ratio of 5.68. The stock’s 50-day simple moving average is $6.52 and its 200-day simple moving average is $7.92.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MRNS. HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, April 16th. Truist Financial reduced their target price on Marinus Pharmaceuticals from $25.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, April 17th. StockNews.com downgraded Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Robert W. Baird reiterated a “neutral” rating on shares of Marinus Pharmaceuticals in a research report on Tuesday, April 16th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $3.00 price target (down previously from $24.00) on shares of Marinus Pharmaceuticals in a report on Monday, April 15th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $16.07.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.